Table 3. Prognostic factors affecting survival outcomes on univariate analysis.
| |
|
LRRFS |
DFS |
OS |
|||
|---|---|---|---|---|---|---|---|
| Variables | n | 5-year rate | P | 5-year rate | P | 5-year rate | P |
| ENI |
|
|
0.9716 |
|
0.7328 |
|
0.6686 |
| No | 124 | 95.9% | 90.2% | 96.7% | |||
| Yes |
136 |
95.3% |
|
90.9% |
|
96.2% |
|
| Age |
|
|
0.3540 |
|
0.0770 |
|
0.9058 |
| <40 years | 71 | 95.8% | 87.3% | 97.1% | |||
| ⩾40 years |
189 |
95.5% |
|
91.8% |
|
96.2% |
|
| Clinical T |
|
|
0.5083 |
|
0.7017 |
|
0.0804 |
| cT1–2 | 203 | 94.8% | 89.9% | 95.4% | |||
| cT3–4 |
57 |
98.2% |
|
92.7% |
|
100% |
|
| Molecular subtype |
|
|
0.8601 |
|
0.7186 |
|
0.7447 |
| Luminal | 95 | 95.4% | 92.2% | 97.9% | |||
| Triple-negative | 62 | 96.8% | 88.7% | 96.8% | |||
| HER2-positive |
73 |
95.7% |
|
93.0% |
|
95.5% |
|
| NAC regimen |
|
|
0.7028 |
|
0.3752 |
|
0.7439 |
| AT | 107 | 96.2% | 90.6% | 97.2% | |||
| AC | 72 | 97.0% | 92.8% | 97.1% | |||
| Taxane | 30 | 92.1% | 92.1% | 96.7% | |||
| Others |
51 |
93.8% |
|
86.1% |
|
93.3% |
|
| No. of sampled LNs |
|
|
0.1609 |
|
0.0099 |
|
0.0984 |
| <13 | 105 | 93.5% | 85.0% | 94.9% | |||
| ⩾13 |
155 |
96.7% |
|
94.1% |
|
97.4% |
|
| Pathologic T |
|
|
0.1074 |
|
0.0086 |
|
0.0012 |
| ypT0-is | 102 | 98.0% | 97.0% | 100% | |||
| ypT1 | 116 | 93.4% | 86.6% | 91.9% | |||
| ypT2-4 |
42 |
95.2% |
|
85.6% |
|
100% |
|
| Hormone treatment |
|
|
0.8870 |
|
0.4400 |
|
0.7767 |
| Yes | 103 | 94.8% | 91.8% | 96.9% | |||
| No | 157 | 96.1% | 89.7% | 96.1% | |||
Abbreviations: DFS=disease-free survival; ENI=elective nodal irradiation; HER2=human epidermal growth factor receptor-2; LN=lymph node; LRRFS=locoregional recurrence-free survival; NAC=neoadjuvant chemotherapy; OS=overall survival.